<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622735</url>
  </required_header>
  <id_info>
    <org_study_id>UP-CLI-2019-002</org_study_id>
    <nct_id>NCT04622735</nct_id>
  </id_info>
  <brief_title>Nefopam/Paracetamol Fixed Dose Combination in Acute Pain After Impacted Third Molar Extraction</brief_title>
  <official_title>A Comparative, Randomized, Double-blind, 3-arm Parallel, Phase III Study to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Nefopam/Paracetamol Taken Orally in Moderate to Severe Pain After Impacted Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unither Pharmaceuticals, France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EXCELYA Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unither Pharmaceuticals, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the analgesic efficacy of single and multiple doses of a new&#xD;
      fixed dose combination of nefopam hydrochloride 30 mg and paracetamol 500mg taken orally in&#xD;
      comparison to each single component.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind. Participants, investigators, and all persons involved in the conduct, data management, and analysis of the study will be fully blinded to the participant's treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ranked endpoints : 1. Sum of Pain Intensity Differences at 6 hours (SPID0-6h)</measure>
    <time_frame>6 hours post-dose</time_frame>
    <description>Pain intensity difference will be calculated using the score of pain intensity assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min,) after the first IMP intake and/or right before first intake of rescue medication using a 100-mm Visual Analogic Scale (VAS) compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Pain Relief at 6 hours (TOTPAR0-6h)</measure>
    <time_frame>6 hours post-dose</time_frame>
    <description>Pain Relief will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min) after the first IMP intake and/or right before first intake of rescue medication using a 5-point verbal rating scale (VRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of responder patients</measure>
    <time_frame>6 hours post-dose</time_frame>
    <description>A responder patient is a subject who achieves a reduction of 50% of pain intensity compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Patient's Global Impression of Change (PGIC) questionnaire</measure>
    <time_frame>6 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The onset of pain relief</measure>
    <time_frame>during the first 6 hours</time_frame>
    <description>Score of pain intensity will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240, T300, T360 min). The time point of the first assessment obtaining a score â‰¤ 30 mm will be retained as time score of onset of pain relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief at 1 hour (TOTPAR0-1h), 2 hours (TOTPAR0-2h), 3 hours (TOTPAR0-3h), and 4 hours (TOTPAR0-4h)</measure>
    <time_frame>At 1 hour, 2 hours, 3 hours, and 4 hours</time_frame>
    <description>Pain relief (PAR) will be assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240 min) after the first IMP intake and/or right before first intake of rescue medication using a 5-point verbal rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences at 1 hour (SPID0-1h), 2 hours (SPID0-2h), 3 hours (SPID0-3h), and 4 hours (SPID0-4h)</measure>
    <time_frame>At 1 hour, 2 hours, 3 hours, and 4 hours</time_frame>
    <description>PID will be calculated using the score of pain intensity assessed by the patient at defined time points (T30, T45, T60, T90, T120, T150, T180, T240 min) after the first IMP intake and/or right before first intake of rescue medication using a 100-mm VAS compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pain Intensity Differences (PID) assessment</measure>
    <time_frame>At each timepoint: 30min, At 45min, until at 360 min post-dose</time_frame>
    <description>PID will be calculated using the scores of pain intensity (VAS) at each time point compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responder patients.</measure>
    <time_frame>At 1 hour, 2 hours, 3 hours and 4 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the second IMP intake</measure>
    <time_frame>Up to 5 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue medication intake</measure>
    <time_frame>Up to 10 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences (SPID)</measure>
    <time_frame>At days 1, 2, 3, 4 and 5</time_frame>
    <description>PID will be calculated using the score of pain intensity assessed by the patient at defined time points using a 100-mm visual Analog Scale (VAS) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having taken a rescue analgesic treatment throughout the study.</measure>
    <time_frame>Up to 10 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of rescue medication taken.</measure>
    <time_frame>Up to 10 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean duration under rescue medication over the 5 days.</measure>
    <time_frame>Up to 5 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of IMP intakes</measure>
    <time_frame>Up to 5 days after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of Change (PGIC) score</measure>
    <time_frame>Up to 10 days after first dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence and severity of adverse events (serious and non-serious adverse events).</measure>
    <time_frame>Up to 10 days after first dose</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">321</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each dose: 2 tablets (included in masking capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol 500 mg (X2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each dose: 2 tablets (included in masking capsule)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nefopam hydrochloride 30 mg (X2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each dose: 2 tablets (included in masking capsule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>nefopam hydrochloride 30mg / paracetamol 500mg X2</intervention_name>
    <description>The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.</description>
    <arm_group_label>FDC nefopam hydrochloride 30 mg / paracetamol 500 mg (X2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol 500 Mg Oral Tablet X2</intervention_name>
    <description>The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.</description>
    <arm_group_label>Paracetamol 500 mg (X2)</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam HCl 30 MG Oral Tablet X2</intervention_name>
    <description>The first intake is taken right after randomization. Then on-demand period (5 days maximum) respecting a 6-hour interval between intakes, and up to 3 intakes per day.</description>
    <arm_group_label>Nefopam hydrochloride 30 mg (X2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patient aged from 18 years up to 65 years,&#xD;
&#xD;
          -  Patient scheduled to undergo the surgical removal of at least one fully or partially&#xD;
             impacted third mandibular molar requiring bone removal under short-acting local&#xD;
             anaesthetic (mepivacaine or lidocaine) with or without vasoconstrictor,&#xD;
&#xD;
          -  Patient weighing &gt; 50 kg,&#xD;
&#xD;
          -  Patient who has signed a written informed consent prior to any study-related&#xD;
             procedures.&#xD;
&#xD;
        Additional inclusion criteria after surgery (randomization):&#xD;
&#xD;
          1. Patient experiencing moderate to severe pain within 4 hours after the dental&#xD;
             extraction, defined by a baseline pain intensity Visual Analogic Scale (VAS) score â‰¥&#xD;
             50 mm,&#xD;
&#xD;
          2. Third molar extraction(s) completed without any immediate complication, that in the&#xD;
             opinion of the investigator, would interfere with the study conduct and/or assessments&#xD;
             (e.g., suspected neurosensory complication, incomplete removal of tooth)&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated by analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) within&#xD;
             3 days preceding the day of randomization or within 5 times the elimination half-life&#xD;
             whichever the longest,&#xD;
&#xD;
          -  Woman with positive results on a urine pregnancy test or breastfeeding woman or woman&#xD;
             of childbearing potential without an effective contraception,&#xD;
&#xD;
          -  Patient with a history of convulsive disorders,&#xD;
&#xD;
          -  Patient taking mono-amine-oxidase (MAO) inhibitors (including but not limited to&#xD;
             selegiline, isocarboxazid, tranylcypromine, phenelzineâ€¦),&#xD;
&#xD;
          -  Patient with an abnormal cardiac condition: medically significant disorders of cardiac&#xD;
             rate and/or rhythm,&#xD;
&#xD;
          -  Patient with known anaemia,&#xD;
&#xD;
          -  Patient with known pulmonary disease,&#xD;
&#xD;
          -  Patient with known active gastric or duodenal ulcer or a history of recurrent&#xD;
             gastrointestinal ulcer/bleeding,&#xD;
&#xD;
          -  Patient with known glaucoma,&#xD;
&#xD;
          -  Patients with a prostatic hyperplasia or urinary retention,&#xD;
&#xD;
          -  Patient with current or chronic history of liver disease, or known hepatic or biliary&#xD;
             abnormalities,&#xD;
&#xD;
          -  Patient with a current or chronic history of severe renal impairment (glomerular&#xD;
             filtration below 30 mL/min),&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>International Study Coordinator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Birmingham School of Dentistry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CRO's office</last_name>
    <phone>+33 (0)5 57 77 85 07</phone>
    <email>metapain@itecservices.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HIA Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de tours</name>
      <address>
        <city>Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Center for interdisciplinary dentistry &amp; neuro</name>
      <address>
        <city>Moscow</city>
        <zip>141207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional clinical hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham School of Dentistry</name>
      <address>
        <city>Birmingham</city>
        <zip>B5 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Dental Hospital</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edinburgh Dental Institute</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH3 9HX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>BARTS HEALTH NHS TRUST Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe acute pain</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Third molar extraction</keyword>
  <keyword>Analgesics</keyword>
  <keyword>Nefopam</keyword>
  <keyword>Paracetamol</keyword>
  <keyword>Multimodal analgesia</keyword>
  <keyword>Fixed drug combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

